TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17570651

Group type: EXPERIMENTAL
Intervention: Sibutramine 10mg with low-calorie diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day with low-calorie diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-calorie diet only
Number of subjects: 60
Study: 15970733

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 127

Group type: COMPARATOR
Intervention: Normobaric oxygen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cognitive sequelae and suicide attempt
Number of subjects: 127

Group type: COMPARATOR
Intervention: No cognitive sequelae or suicide attempt
Number of subjects: 127
Study: 12698218

Group type: EXPERIMENTAL
Intervention: Ethanol condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study: 10319358

Group type: EXPERIMENTAL
Intervention: Structured triacylglycerol (STG) emulsion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physical mixture of long‐chain triacylglycerols/medium‐chain triacylglycerols (LCT/MCT) emulsion
Number of subjects: 40
Study: 8733039

Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg 12-hourly
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg once daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1937072

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (5 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (10 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (50 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BW245C (2.5 micrograms)
Number of subjects: 0
Study: 7146854

Group type: EXPERIMENTAL
Intervention: Standardized notice
Number of subjects: 222

Group type: COMPARATOR
Intervention: Manufacturer's notice
Number of subjects: 222
Study: 30985556

Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF
Number of subjects: 670

Group type: COMPARATOR
Intervention: Baseline Regimen
Number of subjects: 670
Study: 28710205

Group type: EXPERIMENTAL
Intervention: Interdisciplinary protocol
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Intervention + healthy food supplement (30 g walnuts/day)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 439
Study: 26050853

Group type: EXPERIMENTAL
Intervention: Tualang honey + antibiotic
Number of subjects: 63

Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 63
Study: 23429699

Group type: EXPERIMENTAL
Intervention: Carvedilol, ramipril (or candesartan if ramipril was not tolerated), spironolactone, and furosemide
Number of subjects: 66
Study: 21209031

Group type: EXPERIMENTAL
Intervention: Antiandrogenic oral contraceptive
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (women without hyperandrogenism)
Number of subjects: 34
Study: 19805783

Group type: EXPERIMENTAL
Intervention: Basic science group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Structured algorithm group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Feature list group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study: 16405274

Group type: EXPERIMENTAL
Intervention: Nasal xylometazoline (XYLO) 0.1% (1 spray each nostril)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal mometasone furoate (MF) 200 mcg daily
Number of subjects: 36
Study: 12601116

Group type: EXPERIMENTAL
Intervention: Anti-CD3-stimulated CD8+ T cells from patients with SPMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 10500311

Group type: COMPARATOR
Intervention: Standard therapy (20 mg IV bolus followed by 60 mg infusion over 1 hour)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single bolus (80 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Split bolus (2 x 40 mg at 30-minute intervals)
Number of subjects: 13
Study: 8634569

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1785240

Group type: EXPERIMENTAL
Intervention: Aminophylline (3 mg.kg‐1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.04 mg.kg‐1)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 6341720

Group type: EXPERIMENTAL
Intervention: Rigorous glucose control
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Improved blood glucose control
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Degree of abnormal nerve function at entry
Number of subjects: 33
Study: 31306374

Group type: EXPERIMENTAL
Intervention: Corticotomy combined with bone graft
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Corticotomy alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Corticotomy combined with PRF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corticotomy-assisted rapid orthodontics
Number of subjects: 30
Study: 28144914

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including long-term structured physical activity, nutritional counseling/dietary intervention, and an information and communication technology intervention
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Healthy aging lifestyle education program
Number of subjects: 1500
Study: 23438441

Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Control group (comparative schools)
Number of subjects: 2038
Study: 22456254

Group type: EXPERIMENTAL
Intervention: Increase in the number of pro-drinkers
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Increase in the number of pro-abstainers
Number of subjects: 1726
Study: 19150139

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (O/A)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Codeine/acetaminophen (C/A)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 154
Study: 17517240

Group type: EXPERIMENTAL
Intervention: Central reader interpretations
Number of subjects: 326

Group type: COMPARATOR
Intervention: Local interpretations
Number of subjects: 326
Study: 15968928

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 18
Study: 14569512

Group type: EXPERIMENTAL
Intervention: 4 cycles of Adriamycin/Cyclophosphamide followed by 4 cycles of Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical response evaluation after 2 cycles of chemotherapy
Number of subjects: 0
Study: 10533734

Group type: EXPERIMENTAL
Intervention: Intrasphincteric injection of botulinum toxin A (20 U injected into each of the four quadrants in the lower esophageal sphincter)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Balloon dilation
Number of subjects: 24
Study: 8923549

Group type: EXPERIMENTAL
Intervention: Cyclopean objects (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocularly visible objects (M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclopean inducers (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monocular inducers (M)
Number of subjects: 0
Study: 1824760

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6874173

Group type: EXPERIMENTAL
Intervention: 6 g of potassium‐magnesium aspartate over a 24‐h period
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 6 g of potassium‐magnesium aspartate
Number of subjects: 8
Study: 29985223

Group type: EXPERIMENTAL
Intervention: Hexagonal Bar (HEX)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Barbell (BAR)
Number of subjects: 29
Study: 30764778

Group type: EXPERIMENTAL
Intervention: Number of diagnosed chronic conditions
Number of subjects: 43501

Group type: EXPERIMENTAL
Intervention: Final parsimonious model including age, sex, and concession card status
Number of subjects: 43501

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 43501

Group type: EXPERIMENTAL
Intervention: Commonwealth Concessional Health Care Card holders
Number of subjects: 43501

Group type: EXPERIMENTAL
Intervention: Each chronic condition
Number of subjects: 43501

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 43501
Study: 30012909

Group type: EXPERIMENTAL
Intervention: Double-level Retrolaminar Paravertebral Block (RLB) with 15 ml ropivacaine (0.5%) for each lamina of T2 and T4 vertebrae
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group received the same volume of normal saline at each level
Number of subjects: 122
Study: 26910598

Group type: EXPERIMENTAL
Intervention: CPAP (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no CPAP, n=24)
Number of subjects: 50
Study: 25215617

Group type: EXPERIMENTAL
Intervention: Interactive game-based training platforms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional task-based training
Number of subjects: 60
Study: 23072517

Group type: EXPERIMENTAL
Intervention: Physical activity plus fatigue management intervention
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Physical activity-only intervention
Number of subjects: 189

Group type: COMPARATOR
Intervention: Contact-control social support intervention
Number of subjects: 189
Study: 20109087

Group type: EXPERIMENTAL
Intervention: NAL-NL1
Number of subjects: 48

Group type: COMPARATOR
Intervention: DSL v.4.1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intelligibility judgments
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preference for NAL
Number of subjects: 48
Study: 17592920

Group type: EXPERIMENTAL
Intervention: Lithium added to antidepressants (tricyclics and tetracyclics) for acceleration
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Lithium added to various antidepressants (including SSRIs) for augmentation
Number of subjects: 500
Study: 16234140

Group type: EXPERIMENTAL
Intervention: Intensive training in pelvic floor exercises
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 234
Study: 11897760

Group type: EXPERIMENTAL
Intervention: Bradykinin (100 to 400 ng/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methacholine (3.2 to 12.8 microg/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitroprusside (1.6 to 6.4 microg/min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 32
Study: 10734331

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7572010

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 micrograms kg‐1 min‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (0.5 or 2.5 micrograms kg‐1 min‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2140122

Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E2,MP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E1,EMRR‐‐E2,EMRR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E2,EMRR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E2,MP‐‐E1,EMRR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E1,EMRR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E2,MP‐‐E2,EMRR
Number of subjects: 20
Study: 633779

Group type: EXPERIMENTAL
Intervention: 4 g cephradine with 40 mg furosemide t.i.d. peroral
Number of subjects: 11

Group type: COMPARATOR
Intervention: 4 g cephalothin
Number of subjects: 11
Study: 30552239

Group type: EXPERIMENTAL
Intervention: Mana Tū programme
Number of subjects: 400

Group type: COMPARATOR
Intervention: Wait list for the programme
Number of subjects: 400
Study: 27593879

Group type: EXPERIMENTAL
Intervention: Manual thrust plus MI‐E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MI‐E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual assistance following MIC maneuver
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unassisted cough
Number of subjects: 40
Study: 24709995

Group type: EXPERIMENTAL
Intervention: Synchronous upper-limb movements with mirror visual feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Synchronous upper-limb movements without mirror visual feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Asynchronous upper-limb movements with mirror visual feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Asynchronous upper-limb movements without mirror visual feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 35
Study: 24429861

Group type: EXPERIMENTAL
Intervention: Fusafungine (Bioparox)
Number of subjects: 61
Study: 20804454

Group type: EXPERIMENTAL
Intervention: naproxen etemesil 1200 mg twice daily (n = 61)
Number of subjects: 120

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily (n = 59)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: naproxen etemesil
Number of subjects: 120

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 120
Study: 18439501

Group type: EXPERIMENTAL
Intervention: Transcatheter uterine artery embolization (UAE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Transcatheter uterine artery occlusion (UAO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both UAE and UAO
Number of subjects: 16
Study: 16419643

Group type: EXPERIMENTAL
Intervention: 46 mg GCE once a day
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 93 mg GCE once a day
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 185 mg GCE once a day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 12640589

Group type: EXPERIMENTAL
Intervention: Quetiapine at a mean dose of 24.9 mg/d (range 12.5-37.2 mg/d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Quetiapine at a mean dose of 24.9 mg/d
Number of subjects: 7
Study: 10476745

Group type: EXPERIMENTAL
Intervention: Conventional regimen (chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 116
Study: 8877666

Group type: EXPERIMENTAL
Intervention: 5% sanguinarine (Sa)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Supragingival plaque control (SPC)
Number of subjects: 201
Study: 1706282

Group type: EXPERIMENTAL
Intervention: 0.1 mg of octreotide acetate subcutaneously before pancreatography
Number of subjects: 63

Group type: COMPARATOR
Intervention: Isotonic sodium-chloride
Number of subjects: 63
Study: 6418972

Group type: EXPERIMENTAL
Intervention: Training at 40% above anaerobic threshold
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Training at anaerobic threshold
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Training at 40% below anaerobic threshold
Number of subjects: 29
Study: 30873657

Group type: EXPERIMENTAL
Intervention: Acetazolamide therapy for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Withdrawal phase (control)
Number of subjects: 24
Study: 29307004

Group type: EXPERIMENTAL
Intervention: Clinicians' decision
Number of subjects: 247

Group type: COMPARATOR
Intervention: Leeds criteria
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Agreement in P. aeruginosa status among adults providing sputum samples
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Agreement in P. aeruginosa status among adults > 25 years old
Number of subjects: 247
Study: 25753551

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (vitamin D3)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (culture-negative household contacts)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: MDR‐TB
Number of subjects: 191
Study: 25520340

Group type: EXPERIMENTAL
Intervention: SR71 stem (carbon-fiber-composite)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stability stem (all-metal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SR71 stem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stability stem
Number of subjects: 60
Study: 22450386

Group type: EXPERIMENTAL
Intervention: hT(2)W‐3D‐FLAIR obtained 10 min, 3.5 hours, and 4 hours after GBCM administration in Group A
Number of subjects: 10

Group type: COMPARATOR
Intervention: hT(2)W‐3D‐FLAIR obtained before and 10 min, 4 hours, and 4.5 hours after GBCM administration in Group B
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grades of EH evaluated at 3.5 and 4 hours in Group A
Number of subjects: 10

Group type: COMPARATOR
Intervention: Grades of EH evaluated at 4 and 4.5 hours in Group B
Number of subjects: 10
Study: 20533449

Group type: EXPERIMENTAL
Intervention: Telemedicine care
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study: 18797646

Group type: EXPERIMENTAL
Intervention: Brief intervention and contact (BIC) plus treatment as usual
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1867
Study: 15916253

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cocaine-specific relapse prevention counseling module
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 61
Study: 12919182

Group type: EXPERIMENTAL
Intervention: Tacrolimus with corticosteroids (prednisone)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tacrolimus with daclizumab
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Corticosteroid group (prednisone)
Number of subjects: 65
Study: 11262469

Group type: EXPERIMENTAL
Intervention: Intravenously administered iron sucrose plus recombinant human erythropoietin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenously administered iron sucrose alone
Number of subjects: 40
Study: 9429991

Group type: EXPERIMENTAL
Intervention: High percentage of calories from fat feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate percentage of calories from fat feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low percentage of calories from fat feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrandomly assigned risk factor feedback
Number of subjects: 0
Study: 8509693

Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 3443154

Group type: EXPERIMENTAL
Intervention: Fenoterol 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenoterol 1.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenoterol 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31743554

Group type: EXPERIMENTAL
Intervention: ACP 3%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACP 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31261570

Group type: EXPERIMENTAL
Intervention: YIC therapeutic vaccine
Number of subjects: 53
Study: 29160559

Group type: EXPERIMENTAL
Intervention: Verbal instruction and positive reinforcement
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 37
Study: 25126854

Group type: EXPERIMENTAL
Intervention: PCV13 with polysorbate 80 (P80)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13 without polysorbate 80 (P80)
Number of subjects: 0
Study: 23602291

Group type: EXPERIMENTAL
Intervention: High dose IV omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 88
Study: 21553972

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity advice delivered by professional staff
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity advice delivered by trained volunteer peers
Number of subjects: 181

Group type: COMPARATOR
Intervention: Attention-control arm of staff-delivered telephone support for nutrition
Number of subjects: 181
Study: 19008718

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg for 3 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ramipril 10 mg for 3 months
Number of subjects: 18
Study: 16840396

Group type: EXPERIMENTAL
Intervention: CPAP therapy and respiratory exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (respiratory exercise only)
Number of subjects: 24
Study: 12919430

Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT)
Number of subjects: 605

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 605
Study: 11081989

Group type: EXPERIMENTAL
Intervention: Pycnogenol (100 mg 2-3 times/day for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9322471

Group type: EXPERIMENTAL
Intervention: Epidural bolus of clonidine 150 micrograms plus morphine 2 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% and sufentanil 2 micrograms/mL
Number of subjects: 68
Study: 8139175

Group type: EXPERIMENTAL
Intervention: Enduracin (long-acting nicotinic acid)
Number of subjects: 31
Study: 30856182

Group type: EXPERIMENTAL
Intervention: siPRBCs (stored for 33±4 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: fPRBCs (stored for 10±3 days)
Number of subjects: 19
Study: 30209353

Group type: EXPERIMENTAL
Intervention: Curcumin (180 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Curcumin + Fish Oil (1.2 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fish Oil (1.2 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27228651

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 103